Skip to main content
Livermore
Livermore
ZHEN

Takeda Pharmaceutical Co Ltd

SEC CIK
0001395064
Latest filing
Nov 13, 2025

The latest 13F from Takeda Pharmaceutical Co Ltd covers Q3 2025 (filed Nov 13, 2025): 8 long positions worth $16.4M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Ovid Therapeutics Inc. (OVID) at 59.8%. Livermore has 8 filings on Form 13F from this institution, going back to Q4 2023.

What changed in Q3 2025

Share counts compared with Q2 2025: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
0
Added
1
Est. +$222.8K
Reduced
0
Sold out
3
Est. −$13.9M

Top 5 holdings

Share of this quarter's portfolio value

  1. OVIDOvid Therapeutics Inc.
    59.8%$9.79MHistory
  2. EQEquillium, Inc.
    15.9%$2.61MHistory
  3. XLOXilio Therapeutics, Inc.
    7.6%$1.24MHistory
  4. STTKShattuck Labs, Inc.
    7.5%$1.23MHistory
  5. LYELLyell Immunopharma, Inc.
    5.4%$891.4KHistory

Biggest buys

New and added positions, by estimated amount bought

  1. LYELLyell Immunopharma, Inc.
    +$222.8KAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. LYELLyell Immunopharma, Inc.
    +3.58 pp1.9% → 5.4%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. HLVXHilleVax, Inc.
    −$13.4MSold outHistory
  2. TSBXTurnstone Biologics Corp.
    −$321.6KSold outHistory
  3. THRDThird Harmonic Bio, Inc.
    −$200.0KSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. HLVXHilleVax, Inc.
    −68.43 pp68.4% → 0.0%History
  2. TSBXTurnstone Biologics Corp.
    −1.64 pp1.6% → 0.0%History
  3. THRDThird Harmonic Bio, Inc.
    −1.02 pp1.0% → 0.0%History

Metrics

13F metrics for Q3 2025, computed only from the numbers in the filings. Definitions below.

Portfolio value
$16.4M
−$3.18M (−16.3%) vs. prior quarter
Positions
8
−3 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
1.2%
Q3 2025, one quarter
Average holding period
7.8 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2023), so positions held before then are understated.

13F filings by quarter

8 quarters, going back to Q4 2023. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $327.5M (Q4 2023)

Q4 2023: $327.5MQ1 2024: $289.0MQ2 2024: $232.3MQ3 2024: $38.0MQ4 2024: $26.6MQ1 2025: $16.2MQ2 2025: $19.6MQ3 2025: $16.4M
Q4 2023Q3 2025
13F filings of Takeda Pharmaceutical Co Ltd by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q3 2025Nov 13, 20258$16.4MOVIDEQXLOvs. Q2 2025SEC
Q2 2025Aug 8, 202511$19.6MHLVXOVIDXLOvs. Q1 2025SEC
Q1 2025May 12, 202511$16.2MHLVXOVIDXLOvs. Q4 2024SEC
Q4 2024Feb 12, 202511$26.6MHLVXOVIDXLOvs. Q3 2024SEC
Q3 2024Feb 13, 202510$38.0MHLVXWVEOVIDvs. Q2 2024SEC
Q2 2024Feb 13, 202513$232.3MDNLIHLVXPHATvs. Q1 2024SEC
Q1 2024Feb 13, 202515$289.0MHLVXDNLIPHATvs. Q4 2023SEC
Q4 2023Feb 13, 202514$327.5MHLVXDNLIPHAT–SEC

13D and 13G filings

Companies where Takeda Pharmaceutical Co Ltd reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

1 company, largest stake first.

Companies where Takeda Pharmaceutical Co Ltd owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
OVIDOvid Therapeutics Inc.13G/A12.30%8.78M shares–Feb 3, 20232 filingsDec 9, 2025SEC

Latest filings

28 filings on file made by Takeda Pharmaceutical Co Ltd or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Takeda Pharmaceutical Co Ltd
CompanyFiled (ET)FormStakeChangeEvent dateFiling
OVIDOvid Therapeutics Inc.Dec 9, 20259:02 PM ET13G/A12.30%8.78M shares–Dec 8, 2025SEC
HLVXHilleVax, Inc.Sep 19, 20257:22 AM ET13D/A0.00%0 shares–Below 5%Sep 17, 2025SEC
XLOXilio Therapeutics, Inc.Jul 31, 202413G/AOld format–––SEC
PHATPhathom Pharmaceuticals, Inc.Apr 10, 202413D/AOld format–––SEC
PHATPhathom Pharmaceuticals, Inc.Apr 1, 202413D/AOld format–––SEC
PHATPhathom Pharmaceuticals, Inc.Jan 25, 202413D/AOld format–––SEC
EQEquillium, Inc.Jan 19, 202413GOld format–New–SEC
CALACalithera Biosciences, Inc.May 26, 20237:08 AM ET13D/AOld format–––SEC
DAWNDay One Biopharmaceuticals, Inc.Feb 3, 202313G/AOld format–––SEC
OVIDOvid Therapeutics Inc.Feb 3, 202313G/AOld format–––SEC
HLSQTessera Defense & Homeland Security Inc.Aug 5, 202213G/AOld format–––SEC
CALACalithera Biosciences, Inc.Jul 6, 202213D/AOld format–––SEC
HLVXHilleVax, Inc.May 9, 202213DOld format–New–SEC
CALACalithera Biosciences, Inc.Apr 21, 202213DOld format–New–SEC
XLOXilio Therapeutics, Inc.Jan 14, 202213GOld format–New–SEC
STTKShattuck Labs, Inc.Jan 14, 202213G/AOld format–––SEC
DAWNDay One Biopharmaceuticals, Inc.Jan 14, 202213GOld format–New–SEC
PHATPhathom Pharmaceuticals, Inc.Nov 12, 202113D/AOld format–––SEC
MIRMMirum Pharmaceuticals, Inc.Oct 25, 202113G/AOld format–––SEC
HLSQTessera Defense & Homeland Security Inc.Oct 18, 202113G/AOld format–––SEC